Compare BioNano Genomics Inc (BNGO) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs The Coca-Cola Co K — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while The Coca-Cola Co K trades at $85.85 (market cap $372.08B). The key difference: The Coca-Cola Co K is far larger — about 27238.7× BioNano Genomics Inc's market cap, and The Coca-Cola Co K pays a 2.45% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KO | |
|---|---|---|
Market Cap | $13.66M | $372.08B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $89.08 |
52-Week Low | $1.06 | $65.67 |
Enterprise Value | $16.26M | $399.26B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Coca-Cola (KO) trades at $86.87, down 0.21% today, with a bullish technical signal supported by moving averages and RSI near 69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
KO offers a solid dividend history with 64 consecutive years of increases, but faces risks from regional demand divergence and high debt. Analysts are bullish with a $95.83 price target, implying 10% upside, though valuation multiples like P/E of 25.97 suggest premium pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
